Compare VTOL & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTOL | ARDX |
|---|---|---|
| Founded | 1948 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2011 | 2014 |
| Metric | VTOL | ARDX |
|---|---|---|
| Price | $46.57 | $5.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $58.00 | $15.14 |
| AVG Volume (30 Days) | 155.6K | ★ 3.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | ★ 34.58 | N/A |
| EPS | ★ 4.32 | N/A |
| Revenue | ★ $1,490,512,000.00 | $2,607,000.00 |
| Revenue This Year | $11.64 | $37.75 |
| Revenue Next Year | $5.59 | $34.24 |
| P/E Ratio | $10.78 | ★ N/A |
| Revenue Growth | ★ 5.30 | N/A |
| 52 Week Low | $26.53 | $3.50 |
| 52 Week High | $50.28 | $8.40 |
| Indicator | VTOL | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 46.52 |
| Support Level | $42.83 | $5.49 |
| Resistance Level | $49.91 | $6.23 |
| Average True Range (ATR) | 1.32 | 0.24 |
| MACD | -0.32 | 0.02 |
| Stochastic Oscillator | 5.76 | 30.86 |
Bristow Group Inc is the provider of vertical flight solutions. The group provides aviation services to a broad base of offshore energy companies and government entities. Its business comprises three reportable segments: Offshore Energy Services, Government Services, and Other Services. Its customers in Australia, Brazil, Canada, Chile, the Dutch Caribbean, the Falkland Islands, India, Ireland, the Kingdom of Saudi Arabia, Mexico, the Netherlands, Nigeria, Norway, Spain, Suriname, Trinidad, the UK, and the U.S. offshore energy customers use services to transport personnel to, from and between offshore energy installations.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.